Johnson Chemical Pharmaceutical Works Co Ltd (4747) - Net Assets
Based on the latest financial reports, Johnson Chemical Pharmaceutical Works Co Ltd (4747) has net assets worth NT$1.74 Billion TWD (≈ $54.77 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.56 Billion ≈ $80.61 Million USD) and total liabilities (NT$820.26 Million ≈ $25.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Johnson Chemical Pharmaceutical Works Co strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.74 Billion |
| % of Total Assets | 67.94% |
| Annual Growth Rate | 11.23% |
| 5-Year Change | 101.53% |
| 10-Year Change | 105.36% |
| Growth Volatility | 24.21 |
Johnson Chemical Pharmaceutical Works Co Ltd - Net Assets Trend (2009–2025)
This chart illustrates how Johnson Chemical Pharmaceutical Works Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Johnson Chemical Pharmaceutical Works Co worth.
Annual Net Assets for Johnson Chemical Pharmaceutical Works Co Ltd (2009–2025)
The table below shows the annual net assets of Johnson Chemical Pharmaceutical Works Co Ltd from 2009 to 2025. Also explore 4747 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.71 Billion ≈ $53.86 Million |
+0.33% |
| 2024-12-31 | NT$1.70 Billion ≈ $53.68 Million |
+1.91% |
| 2023-12-31 | NT$1.67 Billion ≈ $52.68 Million |
+91.81% |
| 2022-12-31 | NT$871.66 Million ≈ $27.46 Million |
+2.76% |
| 2021-12-31 | NT$848.24 Million ≈ $26.72 Million |
-1.16% |
| 2020-12-31 | NT$858.20 Million ≈ $27.04 Million |
+1.21% |
| 2019-12-31 | NT$847.97 Million ≈ $26.72 Million |
+1.37% |
| 2018-12-31 | NT$836.53 Million ≈ $26.36 Million |
+0.13% |
| 2017-12-31 | NT$835.43 Million ≈ $26.32 Million |
+0.36% |
| 2016-12-31 | NT$832.41 Million ≈ $26.23 Million |
+1.32% |
| 2015-12-31 | NT$821.60 Million ≈ $25.88 Million |
+29.38% |
| 2014-12-31 | NT$635.01 Million ≈ $20.01 Million |
+8.82% |
| 2013-12-31 | NT$583.53 Million ≈ $18.38 Million |
+51.06% |
| 2012-12-31 | NT$386.30 Million ≈ $12.17 Million |
+9.31% |
| 2011-12-31 | NT$353.39 Million ≈ $11.13 Million |
+8.92% |
| 2010-12-31 | NT$324.45 Million ≈ $10.22 Million |
+4.17% |
| 2009-12-31 | NT$311.47 Million ≈ $9.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Johnson Chemical Pharmaceutical Works Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 219.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$52.28 Million | 3.06% |
| Other Components | NT$1.66 Billion | 96.94% |
| Total Equity | NT$1.71 Billion | 100.00% |
Johnson Chemical Pharmaceutical Works Co Ltd Competitors by Market Cap
The table below lists competitors of Johnson Chemical Pharmaceutical Works Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Engenco Ltd
AU:EGN
|
$68.19 Million |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
$68.21 Million |
|
LIG-ES SPAC
KQ:220260
|
$68.21 Million |
|
GOLDGROUP MINING INC.
F:55G0
|
$68.22 Million |
|
Loulis Mills S.A.
AT:KYLO
|
$68.14 Million |
|
Tenax Therapeutics Inc
NASDAQ:TENX
|
$68.11 Million |
|
Huddly AS
OL:HDLY
|
$68.08 Million |
|
Av Gad Holdings Ltd
TA:AVGD
|
$68.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Johnson Chemical Pharmaceutical Works Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,703,906,000 to 1,709,471,000, a change of 5,565,000 (0.3%).
- Net income of 53,505,000 contributed positively to equity growth.
- Dividend payments of 78,631,000 reduced retained earnings.
- Other factors increased equity by 30,691,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$53.51 Million | +3.13% |
| Dividends Paid | NT$78.63 Million | -4.6% |
| Other Changes | NT$30.69 Million | +1.8% |
| Total Change | NT$- | 0.33% |
Book Value vs Market Value Analysis
This analysis compares Johnson Chemical Pharmaceutical Works Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.26x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.86x to 1.26x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$27.83 | NT$23.80 | x |
| 2018-12-31 | NT$27.87 | NT$23.80 | x |
| 2019-12-31 | NT$28.25 | NT$23.80 | x |
| 2020-12-31 | NT$28.59 | NT$23.80 | x |
| 2021-12-31 | NT$28.26 | NT$23.80 | x |
| 2022-12-31 | NT$29.04 | NT$23.80 | x |
| 2023-12-31 | NT$19.14 | NT$23.80 | x |
| 2024-12-31 | NT$18.96 | NT$23.80 | x |
| 2025-12-31 | NT$18.83 | NT$23.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Johnson Chemical Pharmaceutical Works Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.39%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.22x
- Recent ROE (3.13%) is below the historical average (7.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 5.25% | 9.20% | 0.48x | 1.18x | NT$-14.81 Million |
| 2010 | 6.99% | 11.27% | 0.51x | 1.22x | NT$-9.76 Million |
| 2011 | 11.14% | 16.05% | 0.56x | 1.25x | NT$4.02 Million |
| 2012 | 12.62% | 18.30% | 0.59x | 1.18x | NT$10.12 Million |
| 2013 | 11.27% | 20.98% | 0.46x | 1.17x | NT$7.43 Million |
| 2014 | 11.27% | 19.76% | 0.48x | 1.18x | NT$8.06 Million |
| 2015 | 7.56% | 16.34% | 0.41x | 1.12x | NT$-20.03 Million |
| 2016 | 7.62% | 16.17% | 0.41x | 1.15x | NT$-19.80 Million |
| 2017 | 7.18% | 15.21% | 0.42x | 1.11x | NT$-23.53 Million |
| 2018 | 6.85% | 13.91% | 0.44x | 1.12x | NT$-26.37 Million |
| 2019 | 7.60% | 15.16% | 0.45x | 1.12x | NT$-20.33 Million |
| 2020 | 7.41% | 14.99% | 0.39x | 1.28x | NT$-22.26 Million |
| 2021 | 5.79% | 11.93% | 0.40x | 1.21x | NT$-35.72 Million |
| 2022 | 7.44% | 13.11% | 0.48x | 1.19x | NT$-22.31 Million |
| 2023 | 4.77% | 13.14% | 0.30x | 1.19x | NT$-87.49 Million |
| 2024 | 4.94% | 13.76% | 0.31x | 1.15x | NT$-86.27 Million |
| 2025 | 3.13% | 9.39% | 0.27x | 1.22x | NT$-117.44 Million |
Industry Comparison
This section compares Johnson Chemical Pharmaceutical Works Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,834,679,900
- Average return on equity (ROE) among peers: 7.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Johnson Chemical Pharmaceutical Works Co Ltd (4747) | NT$1.74 Billion | 5.25% | 0.47x | $68.18 Million |
| Grape King Bio Ltd (1707) | $2.08 Billion | 18.27% | 0.54x | $403.71 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $314.71 Million |
| Maywufa Co Ltd (1731) | $1.72 Billion | 4.41% | 0.55x | $86.89 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.51 Billion | 2.32% | 0.11x | $452.16 Million |
| Lotus Pharmaceutical Co Ltd (1795) | $7.70 Billion | 0.10% | 1.03x | $1.49 Billion |
| GeneFerm Biotechnology Co Ltd (1796) | $892.84 Million | 13.96% | 0.32x | $38.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $1.02 Billion | 0.09% | 0.04x | $141.28 Million |
| YungShin Global Holding Corp (3705) | $6.16 Billion | 14.50% | 0.50x | $469.95 Million |
| TTY Biopharm Co Ltd (4105) | $8.05 Billion | 19.36% | 0.41x | $615.74 Million |
| Phytohealth Corp (4108) | $2.08 Billion | -9.93% | 0.06x | $70.71 Million |
About Johnson Chemical Pharmaceutical Works Co Ltd
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. It offers its products in various therapeutic areas, including central nervous system, respiratory, card… Read more